![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Cobicistat versus Ritonavir
as Pharmacoenhancers of Atazanavir in
Combination with Emtricitabine/Tenofovir DF -
Phase 3 Randomized, Blinded, Active-Controlled Trial,
Week 144 Results
|
|
|
Reported by Jules Levin
ICAAC
54th Interscience Conference on Antimicrobial Agents and Chemotherapy
Washington, DC
September 5-9, 2014
J. Gallant1, E. Koenig2, J. Andrade-Villanueva3, P. Chetchotisakd4, E. DeJesus5, F. Antunes6, K. Arasteh7, G. Moyle8, G. Rizzardini9 J. Fehr10, H. Lui11, L. Zhong11, M. Abram11, H. Cao11, A. Cheng11, and J. Szwarcberg11
1Southwest Care Center, Santa Fe, NM, US; 2Instituto Dominicano de Estudios Virologicos -IDEV-, Santo Domingo, Dominican Republic; 3Hospital Civil, Guadalajara, Mexico; 4Khon Kaen University, Muang District, Thailand; 5Orlando Immunology Center, Orlando, US; 6Hospital de Santa Maria, Lisboa, Portugal; 7EPIMED / Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 8Chelsea & Westminster Hospital, London, United Kingdom; 9Ospedale Luigi Sacco, Milano, Italy; 10University Hospital Zurich, Zurich, Switzerland; 11Gilead Sciences, Inc., Foster City, US
![ICAAC1.gif](../images/090814/090814-5/ICAAC1.gif)
![ICAAC2.gif](../images/090814/090814-5/ICAAC2.gif)
![ICAAC3.gif](../images/090814/090814-5/ICAAC3.gif)
![ICAAC4.gif](../images/090814/090814-5/ICAAC4.gif)
![ICAAC5.gif](../images/090814/090814-5/ICAAC5.gif)
![ICAAC6.gif](../images/090814/090814-5/ICAAC6.gif)
![ICAAC7.gif](../images/090814/090814-5/ICAAC7.gif)
![ICAAC8.gif](../images/090814/090814-5/ICAAC8.gif)
![ICAAC9.gif](../images/090814/090814-5/ICAAC9.gif)
![ICAAC10.gif](../images/090814/090814-5/ICAAC10.gif)
![ICAAC11.gif](../images/090814/090814-5/ICAAC11.gif)
![ICAAC12.gif](../images/090814/090814-5/ICAAC12.gif)
![ICAAC13.gif](../images/090814/090814-5/ICAAC13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|